A study with InO vs. ALLR3 in treating childhood leukemia
- Conditions
- Acute Lymphoblastic Leukemia (ALL)MedDRA version: 21.0Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2022-000186-40-SK
- Lead Sponsor
- Pfizer Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 100
1. Male or female participants between 1 and less than 18 years of age.
Type of Participant and Disease Characteristics:
2. Morphologically confirmed diagnosis of first relapse HR BCP ALL;
HR first relapse is defined as relapse occurring within 18 to 30 months of
original diagnosis of ALL or within 6 months of completion of primary
therapy, and lacking any identified very high risk genetic abnormalities
(ie, KMT2A-rearrangements, TCF3-HLF, TCF3-PBX1, hypodiploidy [<45
chromosomes], TP53 alteration)
• CD22-positive ALL as defined by local institution;
• Bone marrow involvement of = 5% leukemic blasts (= M2 status).
Other Inclusion Criteria:
3. Adequate serum chemistry parameters:
• An estimated glomerular filtration rate (eGFR) in participants 1 to less
than 2 years of age, or estimated creatinine clearance (eCrCl) in those 2
to less than 18 years of age, =30 mL/min using the recommended
formula
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)
=5 × institutional ULN at the time of randomization or precytoreduction/
general anesthesia;
• Total bilirubin =1.5 × institutional ULN unless the participant has
documented Gilbert's syndrome;
4. Prior history of thrombosis during corticosteroid use and/or
asparaginase are eligible provided the participant receives anticoagulant
prophylaxis per institutional guidelines.
5. Cardiac shortening fraction = 30% by echocardiogram or ejection
fraction > 50% by MUGA.
Are the trial subjects under 18? yes
Number of subjects for this age range: 100
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Medical Conditions:
1. Any history of:
• Prior or ongoing hepatic SOS or prior liver failure [defined as severe acute liver injury with encephalopathy and impaired synthetic function (INR of =1.5)];
• Prior allo-HSCT or CAR T-cell therapy;
• Isolated extramedullary leukemia;
• Confirmed testicular relapse unless orchiectomy was performed prior to randomization;
• Philadelphia-chromosome positive ALL, ie. BCR-ABL/t(9;22) present;
• Presence of Grade 3 or Grade 4 peripheral neuropathy as defined in the Delphi consensus of acute toxic effects for childhood ALL;
• Hypersensitivity to the active ingredient of InO or any of its excipients;
• Hypersensitivity/allergy to PEG-ASP;
• Intolerance to any of the ALLR3 agents (mitoxantrone, vincristine, dexamethasone, asparaginase);
• Grade 3 or Grade 4 pancreatitis due to any cause, as defined by CTCAE v4.03;
• Grade 3 or Grade 4 allergic reaction to a monoclonal antibody;
• Participants not fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy, defined as resolution of all such non-hematologic toxicities to Grade =2 per the NCI CTCAE v 4.03 prior to randomization, with the exception of the laboratory abnormalities as defined by other inclusion/exclusion criteria;
• Down syndrome;
• Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study;
• Charcot-Marie-Tooth disease.
2. Prior/Concomitant Therapy with:
• A calicheamicin-conjugated antibody (eg, InO or gemtuzumab ozogamicin) or prior therapy with a CD22 targeted therapy (immunotoxin or CAR T-cell therapy);
• Cytotoxic therapy within 7 days prior to enrollment, with the
exception of hydroxyurea and corticosteroids which are permitted prior to initiating study intervention. Participants may have receivedintrathecal chemotherapy at any time prior to study entry. NOTE: No waiting period is required for participants who relapse while receiving first-line maintenance chemotherapy.
• Any radiation therapy within 28 days prior to enrollment;
• The last dose of granulocyte stimulating factor (ie, Neupogen or equivalent) administered within 7 days prior to study enrollment and the last dose of pegfilgrastim (Neulasta®) given within 14 days prior to enrollment;
• Less than 3 half-lives elapsed after the last dose of a mAb (eg, rituximab=66 days, epratuzumab=69 days). Participants must not have received blinatumomab within 4 weeks before study enrollment;
• Current use of any prohibited concomitant medication(s) or
participants unwilling/unable to use a permitted concomitant
medication(s);
• Any vaccination with live viral vaccines within 2 weeks of the start of study therapy. Prior/Concurrent Clinical Study Experience:
3. Administration of an IP (eg, drug or vaccine) concurrent with study intervention or within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer). A participant may be eligible if they are in the follow-up phase of an investigational study if they meet the criterion for time elapsed from previous administration of IP. Cases must be discussed with sponsor's medical monitor to judge eligibility.
Diagnostic Assessments:
4. Serum or urine pregnancy test positive at screening.
5. Ba
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method